Cargando…

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Detalles Bibliográficos
Autores principales:	Ali, Amar, Bain, Steve, Hicks, Debbie, Newland Jones, Phillip, Patel, Dipesh C., Evans, Marc, Fernando, Kevin, James, June, Milne, Nicola, Viljoen, Adie, Wilding, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778550/ https://www.ncbi.nlm.nih.gov/pubmed/31321747 http://dx.doi.org/10.1007/s13300-019-0670-y

Ejemplares similares

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
por: Wilding, John P. H., et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
por: Viljoen, Adie, et al.
Publicado: (2023)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Beyond HbA(1c): Environmental Risk Factors for Diabetic Retinopathy
por: Nwanyanwu, Kristen Harris, et al.
Publicado: (2015)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

A View Beyond HbA1c: Role of Continuous Glucose Monitoring
por: Chehregosha, Haleh, et al.
Publicado: (2019)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Translating HbA(1c) measurements into estimated average glucose values in pregnant women with diabetes
por: Law, Graham R., et al.
Publicado: (2017)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Differential Thermal Stability and Oxidative Vulnerability of the Hemoglobin Variants, HbA(2) and HbE
por: Chakrabarti, Abhijit, et al.
Publicado: (2013)

Significantly High HbA(1c) in Diabetic Patient with Hb J: Case Report
por: Wan Nik, Wan Nor Fazila Hafizan, et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Low HbA2 Level in β-Thalassemia Trait
por: ÖZSOYLU, Şinasi
Publicado: (2013)

HbA(1c) measurement and relationship to incident stroke
por: Robson, R., et al.
Publicado: (2016)

Very low HbA1C, is it a problem?
por: Joob, Beuy, et al.
Publicado: (2018)

Engineering of the endogenous HBD promoter increases HbA2
por: Boontanrart, Mandy Y, et al.
Publicado: (2023)

The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control
por: Yoshii, Hidenori, et al.
Publicado: (2022)

Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
por: Fernando, Kevin, et al.
Publicado: (2021)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2012)

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels
por: D’Andrea, Elvira, et al.
Publicado: (2023)

Measurement of HbA1c in multicentre diabetes trials – should blood samples be tested locally or sent to a central laboratory: an agreement analysis
por: Arch, Barbara N., et al.
Publicado: (2016)

Association of visit-to-visit HbA1c variability with cardiovascular diseases in type 2 diabetes within or outside the target range of HbA1c
por: Sun, Bao, et al.
Publicado: (2022)

An Evaluation of Point-of-Care HbA1c, HbA1c Home Kits, and Glucose Management Indicator: Potential Solutions for Telehealth Glycemic Assessments
por: Zaharieva, Dessi P., et al.
Publicado: (2022)

Erratum to: Measurement of HbA1c in multicentre diabetes trials – should blood samples be tested locally or sent to a central laboratory: an agreement analysis
por: Arch, Barbara N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eeqfshudlmt4lv17dkpe3lmuln